Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-001 and Spironolactone in Recurrent Glioblastoma
NCT07431216Phase 2Not yet recruiting
- Sponsor
- Starlight Therapeutics
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
01
Overview
Phase 2, open-label trial of LP-184 in glioblastoma (GBM) and astrocytoma (2 arms), sponsored by Starlight Therapeutics. Primary endpoint: Safety and Tolerability at 2 years. Planned start May 2026; status: not yet recruiting.
02
Drugs
LP-184
03
Conditions
glioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on NCT07431216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07431216.